Skip to main content
. 2016 Dec 8;28(2):e19. doi: 10.3802/jgo.2017.28.e19

Table 1. Clinicopathological characteristics of the patients with SCC or AC/ASC.

Characteristics No. of Patients (%) p
All patients (n=249) SCC (n=225) AC/ASC (n=24)
Age (yr) Mean (SD) 61.5 (12.8) 61.4 (12.9) 62.6 (12.4) NS*
≤50 51.0 (20.5) 46.0 (20.4) 5.0 (20.8) NS
>50 198.0 (79.5) 179.0 (79.6) 19.0 (79.2)
Treatments RT 139.0 (55.8) 129.0 (57.3) 10.0 (41.7) NS
CCRT 110.0 (44.2) 96.0 (42.7) 14.0 (58.3)
FIGO stage IIB 96.0 (38.6) 81.0 (36.0) 15.0 (62.5) 0.039
IIIA 12.0 (4.8) 11.0 (4.9) 1.0 (4.2)
IIIB 124.0 (49.8) 118.0 (52.4) 6.0 (25.0)
IVA 17.0 (8.8) 15.0 (6.7) 2.0 (8.3)
PLN meta Negative 176.0 (70.7) 157.0 (69.8) 19.0 (79.2) NS
Positive 73.0 (29.3) 68.0 (30.2) 5.0 (20.8)
Tumor size (mm) Mean (SD) 52.2 (16.2) 52.6 (16.2) 48.5 (15.5) NS*
≤40 65.0 (26.1) 58.0 (25.8) 7.0 (29.2) NS
>40 184.0 (73.9) 167.0 (84.2) 17.0 (70.8)
Duration of RT (day) Median (min–max) 45.0 (7–84) 45.0 (7–66) 47.5 (35–84) NS
≤55 228.0 (91.6) 208.0 (92.4) 20.0 (83.3) NS
>55 21.0 (8.4) 17.0 (7.6) 4.0 (16.7)
Pretreatment Hb (g/dL) Mean (SD) 11.7 (1.7) 11.7 (1.7) 11.8 (1.9) NS*
<11.0 74.0 (29.7) 68.0 (30.2) 6.0 (25.0) NS
≥11.0 175.0 (70.3) 157.0 (69.8) 18.0 (75.0)
Adjuvant hysterectomy Yes 14.0 (5.6) 9.0 (4.0) 5.0 (20.8) 0.006
No 235.0 (94.4) 216.0 (96.0) 19.0 (79.2)

All statistical tests were 2-sided.

AC, adenocarcinoma; ASC, adenosquamous carcinoma; CCRT, concurrent chemoradiotherapy; FIGO, International Federation of Gynecology and Obstetrics; NS, not significant; PLN, popliteal lymph node; RT, radiotherapy; SCC, squamous cell carcinoma; SD, standard deviation.

*The Wilcoxon rank sum test was used to analyze continuous variables (age, tumor size, and the pretreatment hemoglobin level); Fisher's exact test and the χ2 test were used to analyze categorical variables; The median test was used to analyze continuous variables (the duration of RT).